Clinical trials: Head and Neck Cancers
Locally Advanced Esophageal Squamous Cell Carcinoma
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
- Trial name
- NCT03914443
- Testing
- Nivolumab, 5-FU, CDDP
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- National Cancer Center, Japan
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
- Trial name
- NCT03430843
- Testing
- Tislelizumab, Paclitaxel, Docetaxel
- Where
- 104 sites in United States, Belgium and 9 more
- Volunteers
- 512 people
- Sponsor
- BeiGene
Lung Cancer, Oral Cancer
Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
This is a pilot Phase I open-label randomized single-dose two-period crossover study (in the EDDIS project) evaluating the bioequivalence, pharmacokinetics (PK), safety, and tolerability of inhaled afatinib dimaleate compared…
- Conditions
- Lung Cancer, Oral Cancer, Melanoma
- Trial name
- EDDIS-a1 (NCT06897735)
- Testing
- Afatinib Dimaleat, inhalation of afatinib dimaleate
- Where
- New Zealand
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Petrov, Andrey
Oropharyngeal Dysphagia
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and…
- Trial name
- REVIVE (NCT05421689)
- Testing
- Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, Davis
Stomach Neoplasms, Esophageal Neoplasms
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs.
- Trial name
- NCT00390416
- Testing
- Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neack and Head Cancer, Supervised Execise Program
The SEHNeCa Supervised Exercise Project
Objectives: To evaluate the effectiveness and efficiency of an innovative supervised exercise program for patients with head and neck cancer (SEHNeCa) to ameliorate loss of lean body mass, functional capacity and quality of life…
- Trial name
- SEHNeCa (NCT04658706)
- Testing
- A supervised exercise program, exercise prescription
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Basque Health Service
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Esophageal Squamous Cell Carcinoma
NCI UNC Project ESCC
Background: Esophageal cancer is a common cause of cancer deaths. Most cases of this cancer are esophageal squamous cell carcinoma (ESCC). Many of these cases come from two parts of the world with high-risk.
- Trial name
- NCT03206125
- Where
- 2 sites in Malawi
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma (NPC)
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma.
- Trial name
- NCT06611150
- Testing
- Nab-paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors
To explore a more efficient and scientific clinical treatment plan for acute radiotherapy-induced oral mucositis(RIOM/RTOM).it is hoped that the drug combination can more effectively improve the cure rate of acute RIOM,reduce the…
- Trial name
- NCT05364918
- Testing
- Jeksung combined with anti-radiation spray
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
This trial studies how well digital PET scan works in predicting outcomes in patients with oropharyngeal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced).
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04140513
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Cancer
Phase II Study of TAS-106 to Treat Head and Neck Cancer
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
- Trial name
- NCT00737360
- Testing
- TAS-106
- Where
- 5 sites in United States, Hong Kong and 2 more
- Volunteers
- 27 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
This study is a single-arm, multi-center Phase II clinical trial. As depicted in the following study design diagram, its objective is to observe and assess the efficacy and safety of sintilimab during the perioperative period in…
- Trial name
- NCT07379424
- Testing
- Adjuvant therapy: sintilimab combined with radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- chen chao Professor
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
SUMMARY Rationale: Esophageal cancer (EC) is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide.
- Trial name
- ESCALATE (NCT07359417)
- Testing
- Radiation: MRI guided radiotherapy
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Esophageal Cancer
The Comparison of Single and Multi-incision MIE for Esophageal Cancer
Minimally invasive esophagectomy (MIE) has been gradually adopted as a feasible and effective treatment option for esophageal cancer.
- Trial name
- NCT03646110
- Testing
- Minimally invasive esophagectomy
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
Rationale | Elective neck irradiation is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques.
- Conditions
- Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- PRIMO (NCT05333523)
- Testing
- Sentinel lymph node biopsy guided selective elective neck irradiation, Standard elective neck irradiation
- Where
- 9 sites in Netherlands
- Volunteers
- 242 people
- Sponsor
- Radboud University Medical Center
Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00103259
- Testing
- bortezomib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Cancer
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Standard-of-care treatment options for oropharyngeal cancer often result in long-term side effects that interfere with normal quality of life.
- Trial name
- NCT02225496
- Testing
- Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of Head and Neck
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary…
- Trial name
- NIVOPOSTOP (NCT03576417)
- Testing
- Cisplatin, Nivolumab, RT
- Where
- France
- Volunteers
- 680 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.